Potential health hazard — use of or exposure to this product may cause temporary or medically reversible adverse health consequences.
Mirtazapine Tablets Recalled by Mylan Institutional, Inc. (d.b.a. UDL Laboratories) Due to Presence of Foreign Tablets/Capsules; possibility of Glipizide 10...
What You Should Do
Stop using this product immediately. Do not consume, use, or distribute it.
Return the product to the place of purchase for a full refund. If you have questions, contact Mylan Institutional, Inc. (d.b.a. UDL Laboratories) directly.
Affected Products
Mirtazapine Tablets, USP, 45 mg. Rx only, 100 Tablets (10 X 10). Manufactured by: Mylan Pharmaceuticals Inc, Morgantown, WV ---NDC 51079-088-20
Quantity: 58 UD100 Unit Dose Blister Cards of 10 (10 cards of 10 tablets each)
Why Was This Recalled?
Presence of Foreign Tablets/Capsules; possibility of Glipizide 10 mg tablets commingled
Where Was This Sold?
This product was distributed nationwide across all 50 states.
About Mylan Institutional, Inc. (d.b.a. UDL Laboratories)
Mylan Institutional, Inc. (d.b.a. UDL Laboratories) has 22 total recalls tracked by RecallDetector.
Related Recalls
Icosapent Ethyl Capsules Recalled by Zydus Pharmaceuticals (USA) Inc Due to Failed Tablet/Capsule specifications: Red dots inside capsule and...
Zydus Pharmaceuticals (USA) Inc · March 9, 2026
Product label: Temozolomide Capsules Recalled by Rising Pharma Holding, Inc. Due to Failed Impurities/Degradation Specifications: An out-of-specification result observed during...
Rising Pharma Holding, Inc. · March 3, 2026
Semaglutide Inj. Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report